echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Lianhua Qing cough tablets approved for entry into the new version of the health insurance catalog is expected to become a new business growth point of Ering Pharmaceuticals

    Lianhua Qing cough tablets approved for entry into the new version of the health insurance catalog is expected to become a new business growth point of Ering Pharmaceuticals

    • Last Update: 2021-01-14
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Medicine Network December 30th, December 8th, Toling Pharmaceuticals announced that the company's exclusive products have passed the medical insurance negotiations, and for the first time been included in the National Basic Medical Insurance, Industrial Injury Insurance and Maternity Insurance Drug Catalog (2020) (hereinafter referred to as the "National Health Insurance Directory").
    Lianhua Qing cough "sputum cough" and Lianhua Qing plague "Clear plague detoxification" in coordination with Lianhua Qing cough tablets in May 2020 was approved by the State Drug Administration for listing, registered as Chinese medicine 6.1 class of new drugs, belongs to the 2020 version of the "Drug Registration Management Measures" chinese medicine registration classification "Chinese medicine innovative drugs", ling pharmaceutical industry has the independent and complete intellectual property rights of the drug.
    LianhuaQing cough film first used the theory of Chinese medicine to explore the pathogenesis of trachea-bronchitis, and opened up an effective new way to use the theory of rhinology to guide the prevention and treatment of acute trachea-bronchitis.
    It is worth noting that during the outbreak of neo-crown pneumonia in China, Lianhua Qing cough was approved by the Hebei Provincial Administration of Traditional Chinese Medicine for the treatment of patients with neo-crown pneumonia through the Emergency Filing of the Hebei Provincial Drug Administration, and the results showed that Lianhua Qing cough could improve coughing and sputum symptoms and breathing function in patients with neo-crown pneumonia.
    according to the Minne database data, in 2019 China's urban public, urban communities, county-level public, township health coughing sputum flat wheezing category of chinese medicine sales totaled 13.66 billion yuan, an increase of 6. 1%, of which total sales of oral preparations in 2019 amounted to 11.510 billion yuan, an increase of 9.0% compared to 2018, with sales accounting for 84.3% of these efficacy varieties, showing the market advantage of exported preparations.
    Toling Pharmaceuticals said that Lianhua Qing cough tablets were included in the National Health Insurance Directory (2020 edition), not only in the field of sputum cough medicine has a better market prospects, at the same time its "sputum cough" effect and Lianhua Qing plague capsules / particles against viruses, bacteria The synergy of the "detoxification" of inflammation has important clinical value and application prospects for solving the breathing function in major infectious or infectious diseases of the respiratory system, and helps to further enhance the market competitiveness of the company's products in the field of respiratory diseases, and is expected to become a new business growth point for the company in the future.
    Policy to help Chinese medicine innovation To Ling Pharmaceutical Industry continued to power the State Drug Administration on September 28 issued the "Chinese medicine registration classification and declaration information requirements", in the registration classification of Chinese medicine new compound preparations from the registration classification as 1.1 category, in order to promote chinese medicine innovation to provide a favorable environment.
    recently, the State Drug Administration issued a new article to promote the innovation and development of Traditional Chinese medicine, issued "on the promotion of the implementation of the chinese medicine heritage and innovation development" (hereinafter referred to as "Opinions").
    The Opinion points out that we should promote the innovation and development of Traditional Chinese medicine, promote the construction of normative research capabilities and systems for multi-regional clinical trials, promote the overall improvement of the quality of clinical research on Chinese medicine, construct a "three-in-one" review evidence system, pay more attention to the support role of human experience in the safety and effectiveness of Traditional Chinese medicine, and construct a review evidence system combining Chinese medicine theory, human experience and clinical trials in accordance with the characteristics, research and development laws and practices of Traditional Chinese medicine.
    Ealing Pharmaceuticals also said in the announcement that the inclusion of the lianhua qing cough tablets in the National Health Insurance Directory (2020 edition) reflects the National Health Insurance Administration's recognition of the clinical value of the drug, patient benefits, innovation and other aspects, to encourage the development of innovative Chinese medicine.
    In fact, it is no accident that Lianhua Qing cough entered the medical insurance catalogue, is ling pharmaceutical industry has long been adhering to the "scientific and technological innovation is the core competitiveness of enterprises" concept, and always attach importance to innovative Chinese medicine research and development investment results.
    data show that The ling pharmaceutical industry in recent years, research and development investment has increased significantly.
    , total investment in research and development in 2019 was 515 million yuan, up 44.34 percent year-on-year, and the proportion of research and development investment in operating income reached 8.84 percent.
    the first three quarters of 2020, the research and development expenses of Ling Pharmaceuticals were 390 million yuan, up 48.49 percent year-on-year, ranking among the highest in the industry.
    to date, Toling Pharmaceuticals has 11 patented Chinese medicines, of which 8 are listed in the national medical insurance catalogue and 5 are national-based drugs.
    In January this year, the project "Construction of Chinese Medicine's Pulse Theology and Guidance of Microvascular Lesions Prevention and Control" completed by Yiling Pharmaceutical Subsidiary Hebei Yiling Pharmaceutical Research Institute as the first main research unit won the first prize of the 2019 National Science and Technology Progress Award, which is the only national science and technology progress first prize in the medical and health sector of the year.
    the future, the company will increase the research and development of innovative Chinese medicine, has been clinically approved varieties related to endocrinology, urinary system, digestive system, rheumatism and mental diseases.
    addition, the research varieties covering cardiovascular system, nervous system, respiratory system, endocrine metabolic system, digestive system, gynecology, pediatrics and other diseases, are at different stages of preclinical research.
    of this year, in addition to Lianhua Qing cough tablets to obtain drug registration approval, the company's innovative Chinese medicine medicine puzzle god tablets have also declared new drugs.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.